Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 1

Conditions

Skin Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
MAPRE1 protein, human × Dermatologic × Clear all
NCT04349436 2026-04-22

ARTACUS

Replimune, Inc.

Phase 1/2 Active not recruiting
69 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06216938 2026-04-13

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

University of Pittsburgh

Phase EARLY_PHASE1 Recruiting
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡